Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.

Journal Article (Clinical Trial;Journal Article)

Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; Abbruzzese, JL; Markowitz, AB; Patt, YZ; Daugherty, K

Published Date

  • February 1993

Published In

Volume / Issue

  • 11 / 1

Start / End Page

  • 67 - 69

PubMed ID

  • 8349439

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1007/BF00873914


  • eng

Conference Location

  • United States